QNRX — Quoin Pharmaceuticals Income Statement
0.000.00%
- $2.31m
- -$9.01m
Annual income statement for Quoin Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 20-F | 20-F | 10-K | 10-K |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.27 | 4.07 | 6.06 | 8.84 | 9.38 |
Operating Profit | -6.27 | -4.07 | -6.06 | -8.84 | -9.38 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.72 | -5.26 | -21.5 | -9.38 | -8.69 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.72 | -5.26 | -21.5 | -9.38 | -8.69 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.72 | -5.26 | -21.5 | -9.38 | -8.69 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.72 | -5.26 | -21.5 | -9.45 | -8.69 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.33 | -0.171 | -813 | -24.4 | -9.64 |